Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Targeted Oncology"
DOI: 10.1007/s11523-017-0491-8
Abstract: BackgroundCirculating tumor DNA (ctDNA) has been reported as a prognostic marker in melanoma. In BRAF V600-mutant melanoma, a plasma under-exposure to vemurafenib could favor emerging resistance but no biological data are available to support this… read more here.
Keywords: melanoma; vemurafenib plasma; ctdna; vemurafenib ... See more keywords